Buy & Sell Summit Therapeutics Inc (SMMT) – Summit Therapeutics Inc Price Today
Aura AI Summary
Key Stats
- $13.30BMarket Cap
- HealthSector
- -38.91%3M Drawdown
- $12.72BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 4 daysTypical Hold Time
Summit Therapeutics Inc (SMMT) is currently valued at a market capitalization of $13.30B, with an enterprise value of $12.72B. Over the past 52 weeks, Summit Therapeutics Inc has traded between a low of $13.85 and a high of $29.32, highlighting its annual price range. Over the past three months, Summit Therapeutics Inc has recorded a drawdown of -38.91%, reflecting recent price volatility. On average, investors hold Summit Therapeutics Inc for approximately 4 days, indicating typical investor behavior on the platform.
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Most Recent News
NuScale Power stock plunges 82%, but history shows strong recovery potential after big crashes.
NuScale Power's stock price fell sharply by 82%, marking a significant market crash for the company. Despite this steep decline, historical data suggests that companies experiencing similar crashes often recover strongly, with potential returns up to...
Law firm investigates Clearway Energy board for possible breach of duty
Kahn Swick & Foti, LLC has launched an investigation into Clearway Energy, Inc. for potential breach of fiduciary duty by its board of directors and controlling stockholder. The law firm is encouraging Clearway Energy shareholders to contact them to ...
Law firm investigates Scotts Miracle-Gro after sharp stock drop on poor financial results
Kahn Swick & Foti, LLC has launched an investigation into Scotts Miracle-Gro following the company's announcement of disappointing financial results in August 2023. Scotts reported a 6% decline in quarterly sales, a 420 basis point drop in gross marg...